Pathogenic SMAD6 variants could, therefore, be an additional trigger for PAH manifestation offsetting the balance of the TGF-β pathway and the tightly controlled system of tissue homeostasis governed by proliferation and apoptosis. This evidence concerns the gene SMAD6 and pulmonary arterial hypertension.